Given a paragraph and a claim, classify it this way: If the claim contradicts the evidence present in the paragraph, classify the claim as '0'. If the claim has multiple supporting *AND* contradicting evidences, classify the claim as '1'. If the claim has supporting evidence and the paragraph is in overall favor of the claim, then classify the claim as '2'.

[Q]: Paragraph: Frates is fighting back from a summer health scare that landed him in the hospital while still trying to be a public face of amyotrophic lateral sclerosis, or ALS, a degenerative disease that destroys nerve cells, impairs physical functions and so far has no cure. The former Boston College baseball star, who can no longer speak or move, spent most of July in the hospital battling pneumonia and other infections. In July, a tweet erroneously reporting his demise led to worldwide headlines. Frates wryly countered by posting a short video of himself lying in a hospital bed with Pearl Jam's "Alive" playing in the background. Using a computer system that lets him type out words through eye movements, Frates has been tweeting about his progress to his nearly 30,000 followers, along with regular musings about his family and friends, living with ALS and Boston sports. "lots of down days as you can imagine with als, sometimes you don't feel human," he tweeted Sept. 23. "Today I am definitely feeling sorry for myself, sukxx. but I will bounce back. Eff! you als.. Friggin a hole! !" In the weeks since his July health scare, the 32-year-old has re-emerged to accept honors and accolades across his home state of Massachusetts. Last month, he joined Boston Mayor Marty Walsh, Red Sox officials and the Boston College baseball team on the steps of City Hall to declare Sept. 5 "Pete Frates Day" in Boston. And former Red Sox slugger David Ortiz and other Boston sports legends feted Frates at Fenway Park to mark the release of a new book on his life, "The Ice Bucket Challenge: Pete Frates and the Fight Against ALS." Half the proceeds benefit Frates and his family. Frates' wife, Julie, said it's been a difficult and busy few months, but she couldn't persuade her husband to slow things down even if she wanted to. "He's the one pushing to be out there," she said. "We take all the lead from him." The ice bucket challenge had been around for almost a year to benefit various causes. But Frates is credited with helping focus it on ALS specifically and taking it global using his wide network of supporters as an established ALS advocate. The challenge raised roughly $220 million in 2014, of which $115 million went to the ALS Association. A sequel campaign the next summer raised just over $1 million, according to the association. The ALS Association says it has committed more than $89 million of the 2014 windfall to research. "New, exciting research is just starting to pan out, and that's drawing new talent to ALS research, and a lot of companies are now interested in ALS," said Dr. Nazem Atassi, a Massachusetts General Hospital neurologist whose ALS research benefited from ice bucket challenge money. "It's the perfect environment for drug discovery." Among the most promising developments to come out of research funded by the challenge has been the identification of at least four genes that contribute to the disease, a critical step toward developing new treatments, said Kevin Eggan, a professor at Harvard University who specializes in ALS. Another development that gives the Frates family hope is Radicava, a drug approved in May by the U.S. Food and Drug Administration following testimony from the Frates and other advocates. It's the first new treatment approved specifically for ALS in 22 years. Frates' mother, Nancy, said they're applying to get her son on the drug, even though it's not clear how it might help, given his advanced condition. The medication, which was developed in Japan without funding from the ice bucket challenge, has been shown to slow the disease in recently diagnosed patients. "You just want it to stop," Nancy said. "You want someone to say this disease is not tearing through your loved one's body anymore." ALS is still finding new ways to attack Frates, said his father, John, a city councilor in Beverly who quit his financial services job to help care for his son after he was diagnosed in 2012. Frates' bladder stopped working last year, requiring his urine now to be drained with a catheter every three hours, John Frates said. "It's amazing he's tolerating all of it. It just shows the courage, will and determination he has to be with us," Frates' father said. "He's as incapacitated as a human being can be. That's his quality of life." ___ Follow Philip Marcelo at twitter.com/philmarcelo. His work can be found at https://www.apnews.com/search/philip%20marcelo Claim: ALS patient behind ice bucket challenge: I will bounce back.
[A]: 2

[Q]: Paragraph: Aerus air quality technicians who inspected the Jefferson County Election Commission office last month found evidence of water damage and mold buildup, and an oppressive musty odor permeated the air. "They found mold in the carpet," Commissioner Stuart Soffer said. "In the heating and air room, the readings were unbelievable and there was a pickle bucket in there with water and mold that has been growing because apparently one of the units back there was leaking, and the two air filters were black with mold." Soffer noted that mold was growing inside the cabinets in the media room, where commissioners work to prepare elections and to tabulate election results. He added that the moisture contamination was coming from a building next door that was leaking into the election commission office. "The bottom line is that we cannot continue using this building," he said. "We have a liability and if you knowingly expose people to this stuff, you're setting yourself up." According to the Centers for Disease Control and Prevention, mold can prompt a variety of health problems including eye, nose and throat irritation, but can also lead to lung disease and upper respiratory tract illness for those with asthma or a compromised immune system. Aerus' measurements showed that one election room contained 73,300 particles per cubic foot small mold spores, which technicians said far exceeded acceptable levels of 2,500 particles per cubic foot. They also found large mold spores measuring 16,800 particles per cubic foot, while the acceptable level is 200 particles per cubic foot. The Arkansas Gazette-Democrat reported that the damp and mold could lead to corrosion of electronic voting machines. The technicians said mold spore levels far exceeded acceptable levels. Aerus, which sells air and water purifiers, recommended a $1,500 dehumidifier. Soffer suggested that the election commission could move into the former sheriff's office facility in the county courthouse. But County Judge Gerald Robinson, the chief executive of county government, said that room wasn't available to the election commission. Robinson said he would look for another county-owned building to use. ___ Information from: Arkansas Democrat-Gazette, http://www.arkansasonline.com Claim: Arkansas election office may move due to high mold levels.
[A]: 2

[Q]: Paragraph: This release makes no mention of the costs of the drugs compared in this study, even though the drugs have been in use for years and are widely available. Since the study is a comparison of various treatments for this form of cancer, it seems relevant to offer a cost comparison as well as a comparison of efficacy. It appears that the high dose methotrexate is given over a 24-hour period, presumably in the hospital, while the standard methotrexate is given as a single dose. Also, the high dose methotrexate isfollowed by leucovorin administration while the standard dose is not. According to the site GoodRx, the cost for methotrexate in low-dose (2.5 mg) pill form averages out to about $50 for a month's supply. Newer, injectable variations of the drug cost upwards of $500 a month for the 25 mg dose. The release states that patients receiving high doses of the drug methotrexate "had a significantly better outcome, by 5 to 6 percent" than did patients receiving the current standard of care, which is gradually escalating doses of the drug. The release also explains that patients nine years old or younger who were also treated with a steroid called decadron (dexamethasone) forhalf as long as normal (14 versus 28 days) benefited from the treatment while patients 10 and older did not. We're not sure of the meaning behind these results as portrayed in the release. Which outcome was better by 5 or 6 percent? The study has several. Does that mean the relapse rate was reduced or is it the event free survival that was better? It would be more meaningful to readers if the release had included the actual relapse and event free survival rates for each group analyzed in terms most people can understand. For example: "relapse rates were 5 percent lower in Group X compared to Group Y." We'll give this category a satisfactory rating largely due to the release including information that patients 10 and older receiving dexamethasone "were at much higher risk for a debilitating bone condition called osteonecrosis," although we would have been happier if that greater risk would have been quantified. However, the published study explains that there were toxicity problems beyond that of dexamethasone and the release would have been stronger including that information as well. The release stated the study was randomized and controlled, and provides a broad overview of the study design, for which we give the release a borderline satisfactory under this criteria. However, these are thesuperficial results. On deeper delving into the study methodology, the statistical significances of the results were very close to notstatistically significant. This is due to their planned interim stopping of the treatment and the fact that they were looking at multiple outcomes in multiple groups. This release doesn't demonstrate disease-mongering. While the release does say that this clinical trial was run by the Children's Oncology Group, which is funded by the National Cancer Institute and the National Institutes of Health, it makes no mention of possible conflicts of interest. Compounding that is the fact that the published study says, "Disclosures provided by the authors are available with this article at www.jco.org," but that information is behind the journal's paywall for most readers, so it's unknown if there is, or is not, a conflict. It appears as though five of the authors (out of a total of about 20) have some conflicts of interest, mostly from several types of drug company payments. The release is comparing the efficacy of treatment regimens using different drugs so alternative treatmentsfor B-acute lymphoblastic leukemia are noted. The release makes clear at the end that the treatment of this disease is improving thanks to refinement of the use of existing drug treatments, meaning that they are readily available for patient use. The release suggests the study findings could change the way childhood leukemia is treated. Modifying existing treatments to enhance a patient's survival is certainly novel enough to warrant a release. There is no use of unjustifiable language in this release. However, the tone may be a bit overly optimistic given the study findings. Claim: Relapses of childhood leukemia improve with high doses of common chemo drug
[A]:
2